Overview

Cilostazol Following Peripheral Endovascular Procedures

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
To compare the safety and effectiveness of dual anti-platelet therapy with cilostazol 100 mg twice daily and aspirin 100 mg daily versus monotherapy with aspirin 100 mg daily in patients undergoing peripheral angioplasty or stenting or both for the management of peripheral arterial disease.
Phase:
Phase 3
Details
Lead Sponsor:
Attikon Hospital
Collaborator:
University Hospital of Patras
Treatments:
Aspirin
Cilostazol